P
Paul M. Moseley
Researcher at University of Nottingham
Publications - 48
Citations - 1227
Paul M. Moseley is an academic researcher from University of Nottingham. The author has contributed to research in topics: Breast cancer & DNA repair. The author has an hindex of 20, co-authored 48 publications receiving 988 citations. Previous affiliations of Paul M. Moseley include Nottingham University Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.
Tarek M. A. Abdel-Fatah,Roslin Russell,Nada Albarakati,David J. Maloney,Dorjbal Dorjsuren,Oscar M. Rueda,Paul M. Moseley,Vivek Mohan,Hongmao Sun,Rachel Abbotts,Abhik Mukherjee,Devika Agarwal,Jennifer L. Illuzzi,Ajit Jadhav,Anton Simeonov,Graham Ball,Stephen Chan,Carlos Caldas,Ian O. Ellis,David M. Wilson,Srinivasan Madhusudan +20 more
TL;DR: FEN1 is a promising biomarker in breast and ovarian epithelial cancer and is associated with poor breast cancer specific survival in univariate and multivariate analysis.
Journal ArticleDOI
Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells
Rebeka Sultana,Tarek Mohamed Ahmed Abdel-Fatah,Christina Perry,Paul M. Moseley,Nada Albarakti,Vivek Mohan,Claire Seedhouse,Stephen Chan,Srinivasan Madhusudan +8 more
TL;DR: Evidence is provided that ATR inhibition is suitable for synthetic lethality application and cisplatin chemopotentiation in XRCC1 deficient ovarian cancer cells.
Journal ArticleDOI
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
Tarek M. A. Abdel-Fatah,Devika Agarwal,Dong-Xu Liu,Dong-Xu Liu,Roslin Russell,Oscar M. Rueda,Karen Liu,Bing Xu,Paul M. Moseley,Andrew R. Green,Alan Graham Pockley,Robert C. Rees,Carlos Caldas,Ian O. Ellis,Graham Ball,Stephen Chan +15 more
TL;DR: Factors that drive proliferation and its associated features in breast cancer are identified and their association with clinical outcomes and response to chemotherapy is assessed.
Journal ArticleDOI
Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
Tarek M. A. Abdel-Fatah,Christina Perry,P. D. Dickinson,Graham Ball,Paul M. Moseley,Srinivasan Madhusudan,Ian O. Ellis,Stephen Chan +7 more
TL;DR: Adding Bcl2 to the panel of markers used in current clinical practice could provide both prognostic and predictive information in TNBC, whereas TNBC/Bcl2+ TNBC seems to be resistant to ATC-CT and may benefit from a trial of different type of chemotherapy with/without novel-targeted agents.
Journal ArticleDOI
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer
Tarek M. A. Abdel-Fatah,Fiona K. Middleton,Arvind Arora,Devika Agarwal,Tao Chen,Paul M. Moseley,Christina Perry,Rachel Doherty,Stephen Chan,Andrew R. Green,Emad A. Rakha,Graham Ball,Ian O. Ellis,Nicola J. Curtin,Srinivasan Madhusudan +14 more
TL;DR: Evidence is provided that ATR and CHEK1 are promising biomarkers and rational drug targets for personalized therapy in breast cancer and remain an independent predictor of adverse outcome.